[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100402812":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":24,"centralContacts":28,"locations":34,"responsibleParty":52,"collaborators":54,"id":58,"slug":59,"hasResults":60,"nctId":61,"briefTitle":62,"officialTitle":63,"acronym":18,"eligibilityCriteria":64,"healthyVolunteers":60,"sex":65,"minAge":66,"maxAge":67,"enrollmentInfo":68,"targetDuration":18,"studyType":71,"phases":72,"briefSummary":74,"conditions":75,"keywords":18,"overallStatus":36,"whyStopped":18,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":87},{"fullName":5,"class":6},"National Neuroscience Institute","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Tebonin Forte","EXPERIMENTAL","Treatment: 120mg, twice a day, 52 weeks",[13],"Drug: Tebonin Forte",{"label":15,"type":16,"description":17,"interventionNames":18},"Control","NO_INTERVENTION","No Treatment",null,[20],{"type":21,"name":9,"description":22,"armGroupLabels":23,"otherNames":18},"DRUG","Dietary supplement: Gingko biloba EGb 761",[9],[25],{"name":26,"affiliation":5,"role":27},"Kok Pin Ng","PRINCIPAL_INVESTIGATOR",[29],{"name":30,"role":31,"phone":32,"phoneExt":18,"email":33},"Joanna Wang","CONTACT","(65) 6357 7635","joanna.wang.s@singhealth.com.sg",[35],{"facility":5,"status":36,"city":37,"state":18,"zip":38,"country":37,"countryCode":39,"cosmosGeoPoint":40,"geoPoint":45,"contacts":46},"RECRUITING","Singapore","308433","SG",{"type":41,"coordinates":42},"Point",[43,44],103.85007,1.28967,{"lat":44,"lon":43},[47,50],{"name":30,"role":31,"phone":48,"phoneExt":18,"email":49},"(65) 63577546","ctru@nni.com.sg",{"name":51,"role":27,"phone":18,"phoneExt":18,"email":18},"Nagaendran Kandiah, MRCP;FAMS",{"type":53,"investigatorFullName":18,"investigatorTitle":18,"investigatorAffiliation":18,"oldNameTitle":18,"oldOrganization":18},"SPONSOR",[55],{"name":56,"class":57},"Dr. Willmar Schwabe GmbH & Co. KG","INDUSTRY","100402812","phase-2-egb-761-in-the-syndrome-of-mci-with-concomitant-cvd-100402812",false,"NCT04525144","EGb 761 in the Syndrome of MCI With Concomitant CVD","Evaluating the Role of EGb 761 in the Syndrome of Mild Cognitive Impairment With Concomitant Cerebrovascular Disease (MCI + CVD)","Inclusion Criteria:\n\n* Patients who have been diagnosed with MCI based on the Petersen criteria and Albert MS criteria\n* Patients who have a Global Clinical Dementia Rating Score of 0.5\n* Patients aged 45 to 85 years at study entry\n* Patients who are literate and able to complete the cognitive evaluations in the opinion of the investigators\n* Patients with the presence of CVD, defined as the presence of white matter hyperintensities (WMH) of Fazekas grade 2 or 3 on MRI brain imaging (done up to 12 months prior to recruitment) or CT scans for patients contraindicated from MRI scans\n* Patients who provide written informed consent to participate in the study\n\nExclusion Criteria:\n\n* Participants should not be receiving antidepressants, antipsychotics, benzodiazepines, acetylcholinesterase inhibitors or NMDA antagonists during the study. Additionally, contraindications for EGb 761 as given in the local prescribing information\u002FSummary of Product Characteristics (SmPC) should be observed.","ALL","45 Years","85 Years",{"count":69,"type":70},134,"ESTIMATED","INTERVENTIONAL",[73],"PHASE2","EGb 761 has been demonstrated to be useful in improving cognitive and global clinical outcomes in patients with cognitive impairment or dementia, when administered at a daily dosage of 240mg in randomised controlled trials through several neuroprotective mechanisms of action. The study aims to determine the efficacy and safety profile of EGb 761 as a prescribed clinical drug for patients with MCI + CVD.",[76,77],"Mild Cognitive Impairment","Cerebrovascular Disease","2022-11-14",{"date":80,"type":81},"2022-11-17","ACTUAL",{"date":83,"type":81},"2020-10-26",{"date":85,"type":70},"2026-11",{"name":5,"class":6},1]